Claritin vs Claritin-D During Pregnancy

How do the options compare?

The lens is a clinician's: guideline endorsement, pregnancy evidence, dosing, onset, and tolerability. Cost and formulation notes appear where relevant.

• MotherToBaby reports that loratadine is not expected to raise the chance of birth differences; an early hypospadias signal was not confirmed by later studies. 1
• MotherToBaby states that ACOG advises avoiding pseudoephedrine during the first three months; most studies do not show an overall rise in birth differences, but small studies reported selected uncommon associations. 2
• A systematic review found generally reassuring antihistamine data but substantial variation in exposure definitions, comparison groups, and adjustment for confounders, limiting causal conclusions about individual products. 3
• A cohort comparing 313 first-trimester exposures to a high-dose loratadine-pseudoephedrine combination with 251,230 unexposed pregnancies found no significant overall malformation difference, but the small exposed group and incomplete confounder data limit reassurance. 4
• In a crossover study of eight nursing participants, one 60-milligram pseudoephedrine dose reduced milk production by an average of 24% over the next 24 hours; the small study does not quantify effects from every regimen. 5

Which option makes sense?

The comparison above is intentionally evidence-first, not brand-first. Please consult your healthcare provider to translate it into a plan that fits your pregnancy specifics.

Disclosure: Pregnancy Smart makes supplements that overlap with some options above. This comparison describes the evidence, not our own product; where our formulation is relevant it is named.